10 patients with advanced colorectal cancer were treated with elevated doses of carmustine and mitomycin C. The regimen was potentiated by lonidamine and supported by autologous bone marrow transplantation. The results of this pilot study were encouraging, with a response rate of 50% and a significantly better survival for responders versus non-responders. No appreciable toxicity of the therapy was observed. This aspect, together with the simplicity of the procedure, calls for further investigations to confirm the good therapeutic index of the treatment.
ELEVATED DOSES OF CARMUSTINE AND MITOMYCIN-C, WITH LONIDAMINE ENHANCEMENT AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER - RESULTS FROM A PILOT-STUDY / Franchi, F; Seminara, Patrizia; CODACCI PISANELLI, Giovanni; Bonaiuti, Vpg; Giovagnorio, Francesco; Gualdi, Gianfranco. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 30A:(1994), pp. 1420-1423. [10.1016/0959-8049(93)E0161-I]
ELEVATED DOSES OF CARMUSTINE AND MITOMYCIN-C, WITH LONIDAMINE ENHANCEMENT AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER - RESULTS FROM A PILOT-STUDY
SEMINARA, Patrizia;CODACCI PISANELLI, Giovanni;GIOVAGNORIO, Francesco;GUALDI, GIANFRANCO
1994
Abstract
10 patients with advanced colorectal cancer were treated with elevated doses of carmustine and mitomycin C. The regimen was potentiated by lonidamine and supported by autologous bone marrow transplantation. The results of this pilot study were encouraging, with a response rate of 50% and a significantly better survival for responders versus non-responders. No appreciable toxicity of the therapy was observed. This aspect, together with the simplicity of the procedure, calls for further investigations to confirm the good therapeutic index of the treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
